Knight Therapeutics Inc. announced that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc. Currently approved in the US, JORNAY PM®, is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Financial terms of the agreement were not disclosed. JORNAY PM® is the first and only evening-dosed methylphenidate product commercially available in the United States to treat ADHD in patients 6 years of age and older.

JORNAY PM® consists of microbeads with a delayed-release layer and an extended-release layer. The first layer delays the release of the active ingredient until morning while the extended-release layer controls the release of the active ingredient from the early morning and throughout the day. This unique formulation provides a pharmacokinetic profile that allows ADHD symptom control from the time patients wake up until they go to bed.

JORNAY PM® was studied in two randomized, double-blind, placebo-controlled, phase 3 clinical trials1,2. Both studies met their primary and key secondary endpoints demonstrating a statistically significant and clinically meaningful improvement in ADHD symptoms upon awakening, through the afternoon, and into the evening. JORNAY PM® was submitted for approval in Canada in November 2023.